Literature DB >> 12423242

Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease.

Baptiste A Faucheux1, Marie-Elise Martin, Carole Beaumont, Stéphane Hunot, Jean-Jacques Hauw, Yves Agid, Etienne C Hirsch.   

Abstract

Dopaminergic neurones degenerate during Parkinson's disease and cell loss is most extensive in the subpopulation of melanized neurones located in the substantia nigra pars compacta. Iron accumulation, together with a lack of up-regulation of the iron-storing protein, ferritin, has been reported and may contribute to increased oxidative stress in this region. We investigated the binding activity of iron regulatory protein-1 (IRP1) to the iron-responsive element that precludes ferritin mRNA translation, in the substantia nigra of a group of parkinsonian patients who presented a statistically significant reduction in the number of nigral melanized-neurones and an increased iron content, together with unchanged H-ferritin and L-ferritin subunit levels as compared to matched controls. The levels of ferritin mRNAs and the binding activity of IRP1 to the iron-responsive element of ferritin mRNA did not differ significantly between the two groups. Moreover, there was no detectable contribution of the iron regulatory protein-2 (IRP2) binding activity. No change in IRP1 control of ferritin mRNA translation explains the lack of up-regulation of ferritin expression in cytoplasmic extracts of SNpc that would be normally expected with cytosolic iron accumulation. The data of this study do not favor changes in transcription and post-transcriptional regulation of ferritin expression in Parkinson's disease and suggest a 'compartmentalized' iron accumulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423242     DOI: 10.1046/j.1471-4159.2002.01118.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  Serum iron, vitamin B12 and folic acid levels in Parkinson's disease.

Authors:  Gulizar Madenci; Sule Bilen; Berna Arli; Mustafa Saka; Fikri Ak
Journal:  Neurochem Res       Date:  2012-02-26       Impact factor: 3.996

Review 2.  Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients.

Authors:  Dominic J Hare; Manfred Gerlach; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-09-13       Impact factor: 3.575

3.  Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Authors:  Sanjib Gogoi; Tamara Antonio; Subramanian Rajagopalan; Maarten Reith; Julie Andersen; Aloke K Dutta
Journal:  ChemMedChem       Date:  2011-05-12       Impact factor: 3.466

Review 4.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

Review 5.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

6.  Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.

Authors:  Balaram Ghosh; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

7.  Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

Authors:  Gyan Modi; Chandrashekhar Voshavar; Sanjib Gogoi; Mrudang Shah; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Chem Neurosci       Date:  2014-07-09       Impact factor: 4.418

8.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

Review 10.  Iron-regulatory proteins: molecular biology and pathophysiological implications.

Authors:  Gaetano Cairo; Stefania Recalcati
Journal:  Expert Rev Mol Med       Date:  2007-12-05       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.